| Brite Smiles Dental Care | |
|
8977 Hunters Way Apple Valley MN 55124 | |
| (952) 891-8484 | |
| (952) 891-1256 |
| Full Name | Brite Smiles Dental Care |
|---|---|
| Speciality | Dentist |
| Location | 8977 Hunters Way, Apple Valley, Minnesota |
| Authorized Official Name and Position | Dennis C Simmons (DENTIST) |
| Authorized Official Contact | 9528918484 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Brite Smiles Dental Care 8977 Hunters Way Apple Valley MN 55124 Ph: (952) 891-8484 | Brite Smiles Dental Care 8977 Hunters Way Apple Valley MN 55124 Ph: (952) 891-8484 |
| NPI Number | 1588774152 |
|---|---|
| Provider Enumeration Date | 08/30/2006 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 8325365935 |
|---|---|
| Medicare Enrollment ID | O20150319001073 |
News Archive
A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX.) reduces the risk of colorectal adenomas, or polyps.
Bloomberg reports that shortly after President Barack Obama's re-election, he told senior staff members that the health law would be one of his second term's highest priorities. In related news, health care will be a focus for Obama this week, and it was a hot topic at a recent dinner between the president and House Democrats.
Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.
Malaysian researchers have identified the two species of the Leptospira genus of bacteria responsible for most cases of leptospirosis in the country and discovered a new strain capable of infecting humans.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588774152 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | D8270 (Minnesota) | Primary |
| Provider Name | Dennis Simmons |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1528232782 PECOS PAC ID: 9931424272 Enrollment ID: I20150518002109 |
News Archive
A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX.) reduces the risk of colorectal adenomas, or polyps.
Bloomberg reports that shortly after President Barack Obama's re-election, he told senior staff members that the health law would be one of his second term's highest priorities. In related news, health care will be a focus for Obama this week, and it was a hot topic at a recent dinner between the president and House Democrats.
Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.
Malaysian researchers have identified the two species of the Leptospira genus of bacteria responsible for most cases of leptospirosis in the country and discovered a new strain capable of infecting humans.
› Verified 4 days ago
| Provider Name | Lisa A Edstrom |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1922235027 PECOS PAC ID: 2860712767 Enrollment ID: I20150529002580 |
News Archive
A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX.) reduces the risk of colorectal adenomas, or polyps.
Bloomberg reports that shortly after President Barack Obama's re-election, he told senior staff members that the health law would be one of his second term's highest priorities. In related news, health care will be a focus for Obama this week, and it was a hot topic at a recent dinner between the president and House Democrats.
Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.
Malaysian researchers have identified the two species of the Leptospira genus of bacteria responsible for most cases of leptospirosis in the country and discovered a new strain capable of infecting humans.
› Verified 4 days ago
News Archive
A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX.) reduces the risk of colorectal adenomas, or polyps.
Bloomberg reports that shortly after President Barack Obama's re-election, he told senior staff members that the health law would be one of his second term's highest priorities. In related news, health care will be a focus for Obama this week, and it was a hot topic at a recent dinner between the president and House Democrats.
Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.
Malaysian researchers have identified the two species of the Leptospira genus of bacteria responsible for most cases of leptospirosis in the country and discovered a new strain capable of infecting humans.
› Verified 4 days ago
Synergy Dental Llc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 15322 Galaxie Ave Ste 205, Apple Valley, MN 55124 Phone: 612-601-0050 | |
Orthodontic Care Specialists Ltd Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 14605 Glazier Ave. S., Apple Valley, MN 55124 Phone: 952-432-1103 Fax: 952-891-8678 | |
Apple Valley Family Dentistry Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 7493 147th St W, Suite #100, Apple Valley, MN 55124 Phone: 952-432-7145 Fax: 952-432-6886 | |
Dakota Dental Clinic Pa Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 14682 Pennock Ave, Apple Valley, MN 55124 Phone: 952-431-5774 Fax: 952-431-0862 | |
Healthpartners Apple Valley Dental Clinic Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 15290 Pennock Ln, Apple Valley, MN 55124 Phone: 952-431-8583 Fax: 952-431-8528 | |
Eagan Valley Dental Center Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 14050 Pilot Knob Rd, Apple Valley, MN 55124 Phone: 952-423-4414 | |
Distinctive Dental Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 7631 145th St W, Apple Valley, MN 55124 Phone: 952-432-8696 |